Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (October 2022)
21 slides from Anatara Lifesciences's investor presentation, Oct 13, 2022
Slide 1: Investor Presentation
Anatara Lifesciences Ltd Investor Presentation Oct 2022 ASX: ANR
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company).
Slide 3: Specialising in the Gastrointestinal Tract
Specialising in the Gastrointestinal Tract Evidenced-based solutions for gastrointestinal tract health issues About Anatara Investment Highlights Anatara Lifesciences Ltd (ASX:ANR) is focused on the Novel Technology validation and commercialisation of innovative, evidence- ▪ Gastrointestinal Reprogr
Slide 4: Key Management & Board of Directors
Key Management & Board of Directors Highly experienced Board & Management John Michailidis, COO Dr David Brookes, Executive Chair • John is an executive with more than 30 years’ of • 30+ years international experience in the health and commercial pharmaceutical experience. biotechnology industries •
Slide 5: Active Programs
Active Programs Gastrointestinal RePrograming (GaRP) GaRP is a multi-component complementary medicine, designed to address the underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD including the homeostasis of the microbiome. GaRP-IBS trial currently in Stage 1 w
Slide 6: Human Health
Human Health GaRP progressing towards commercialisation Gastrointestinal RePrograming (GaRP) technology for ‘gut health’ ▪ Active Clinical trial – Irritable Bowel Syndrome ▪ Commenced Sept 2021; Interim readout 1QCY2023 Safety Profile ▪ All components GRAS (generally regarded as safe by FDA) Intelle
Slide 7: GaRP
GaRP One product, multiple benefits Scientifically designed to manage and control background IBS symptoms as well as episodic flare ups Designed as an everyday option to manage the causes and relieve symptoms of IBS (pain, cramping, gas, bloating, diarrhoea & constipation) Coated components released
Slide 8: Gastrointestinal RePrograming (GaRP)
Gastrointestinal RePrograming (GaRP) A potential breakthrough for gut health Unique knowledge of Ingredients are Well-characterised Synergistic effects Gut-Brain bromelain’s ‘fingerprint’ GRAS proprietary mix Connection Function within formulation and potential impact on symptoms Anti- Reduction of
Slide 9: GaRP – Grounded in scientific evidence
GaRP – Grounded in scientific evidence GaRP addresses the underlying factors of gastrointestinal disorders Diseased Gut GaRP gut repair in action GaRP regenerated gut Leaky ‘tight junctions’ allow pathogens Increase in mucin gene expression to Restored ‘tight junctions’ allow the body to enter the b
Slide 10: Snapshot: IBS and IBD
Snapshot: IBS and IBD Gastrointestinal disorders are highly prevalent and poorly managed IBS affects IBD affects 11% >5m of the global population 6 people globally, with accelerating incidence7 Debilitating Symptoms Patients seek alternative options Patients experience symptoms such as pain, bloatin
Slide 11: Market Opportunity
Market Opportunity The gut health market is significant, lacking effective, evidence-based solutions >US$12.5 billion spend on OTC and digestive remedies alone 2,3 $23.4B >US $1 billion market in IBS alone 4 $21.6B $20.0B $18.5B Probiotic Gastrointestinal OTC digestive $17.1B $15.8B supplements supp
Slide 12: Clinical trial – Irritable Bowel Syndrome
Clinical trial – Irritable Bowel Syndrome Robust clinical trial to validate the effectiveness of GaRP Stage 1 Stage 2 110 Patients (randomised, double blind placebo controlled) Cohort 1: 30 Patients on placebo Cohort 1: 55 Patients 90 Patients: on placebo Final results readout Interim Analysis Trial
Slide 13: Advisory Board and DSMB members
Advisory Board and DSMB members Highly accomplished Advisory Board to guide ANR through to commercialisation Advisory Board members are internationally recognised for their expertise in IBS and IBD with experience ranging from preclinical drug development through to translational research and clinic
Slide 14: Licensing discussions & portfolio diversification
Licensing discussions & portfolio diversification Progressing licensing discussions with global consumer health companies for GaRP Global Local Anatara is experiencing inbound interest from global leaders Partnerships with regional leaders in 'gut' health to leverage in the GI field due to the stron
Slide 15: Animal Health
Animal Health Progressing towards commercialisation Detach®, ANR-pf and BONIFF ▪ Orally administered, non-antibiotic products. Know how for products with extracts from pineapple stems for potential delivery in water or on feed mix. ▪ Unlike antibiotics and zinc oxide, will not contribute to antimicr
Slide 16: Contact Anatara Lifesciences Ltd
Contact Anatara Lifesciences Ltd David Brookes, Executive Chair +61 411 712 579 www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd Investor Relations Dirk van Dissel Candour Advisory E: dirk@candouradvisory.com.au
Slide 17: Glossary
Glossary IBS Irritable bowel syndrome (IBS) is a complex condition that affects the colon (large bowel). Key symptoms include abdominal pain or discomfort, stomach bloating, chronic diarrhoea or constipation, or alternating between the two. Inflammatory bowel diseases are conditions in which the lin
Slide 18: What is the gut-brain connection?
What is the gut-brain connection? 23 Pathways between the gut microbiota and the brain, featuring a range of gut molecules ▪ Researchers at Flinders University have released new findings that illustrate how the gut’s cells work in tandem with the spinal cord and brain, in turn influencing people’s c
Slide 19: What is the gut-brain connection?
What is the gut-brain connection? 24 Pathways between the gut microbiota and the brain, featuring a range of gut molecules ▪ The gastrointestinal system offers an integrated interface for regulation of various body functions in health and disease. ▪ The lining of the gut, known as the epithelium, is
Slide 20: Pathophysiology
Pathophysiology 25 ▪ By definition, no structural abnormalities explain Functional Gastrointestinal Disorders (FGIDs) and, on the basis of the biopsychosocial model developed by Engel 34 and adapted by Drossman,35,36 they are characterised as complex bidirectional dysregulations of gut–brain interac
Slide 21: Pathophysiology
Pathophysiology 25 34. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129–36. 35. Van Oudenhove L, Crowell MD, Drossman DA, et al. Biopsychosocial aspects of functional gastrointestinal disorders. Gastroenterology 2016; 150: 1355–67. 36. Drossman DA. Pres
Anatara Lifesciences — Investor Presentation (October 2022) on 6ix